GJGuangyang Jiao

Guangyang Jiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Guangyang Jiao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Wansheng Chen

    The SATCM Key Laboratory for New Resources & Quality Evaluation of Chinese Medicine, Institute of Chinese Materia Medica Shanghai University of Traditional Chinese Medicine Shanghai 201203 China

    2 shared publications
  • Xiangcheng Fan

    Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University (Tongde Hospital of Zhejiang Province)

    2 shared publications
  • Yejian Wang

    Department of Pharmacy Changzheng Hospital Naval Medical University (Second Military Medical University) Shanghai P. R. China

    2 shared publications
  • Doudou Huang

    Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China

    1 shared publication
  • Feng Zhang

    Department of Pharmacy, Changzheng Hospital, Naval Medical University, Shanghai, China

    1 shared publication
  • Feng Zhang

    Department of Pharmacy Changzheng Hospital Naval Medical University (Second Military Medical University) Shanghai P. R. China

    1 shared publication

Latest Publications

  • Combination of ultra‐performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry and network pharmacology to reveal the key effective compounds and mechanism of Shengxian decoction for ameliorating doxorubicin cardiotoxicity

    by Guangyang Jiao, Yejian Wang, Yue Song, Yuxin Chen, Xiangcheng Fan, Qing Zhao, Tao Pang, Feng Zhang, Wansheng Chen

    Shengxian decoction, a traditional Chinese medicinal prescription, has been shown to alleviate doxorubicin‐induced chronic heart failure. This study established an ultra‐performance liquid chromatography‐quadrupole time‐of‐flight mass spectrometry method to separate and characterize the complex chemical compositions of Shengxian decoction, and the absorbed compounds in the bio‐samples of the cardiotoxicity rats with chronic heart failure after its oral delivery. Note that 116 chemical compounds were identified from Shengxian decoction in vitro, 81 more than previously detected. Based on the three‐dimensional data of these compounds, 28 absorbed compounds were confirmed in vivo. Network pharmacology and molecular docking experiments indicated that timosaponin B‐II, timosaponin A‐III, gitogenin, and 7,8‐didehydrocimigenol were recognized as the key effective compounds to exert effects against doxorubicin cardiotoxicity by acting on targets such as caspase 3, cyclin‐dependent kinase 1, cyclin‐dependent kinase 4, receptor tyrosine‐protein kinase erbB‐2, and mitogen‐activated protein kinase 1 in p53 and phosphatidylinositol 3‐kinase‐Akt signaling pathways. This study developed the understanding of the composition of Shengxian decoction for the treatment of doxorubicin cardiotoxicity, as well as a feasible strategy to elucidate the effective constituents in traditional Chinese medicines.


  • Open Access

    Dissection of the Active Ingredients and Potential Mechanism of Han-Shi-Yu-Fei-Decoction in Treating COVID-19 Based on In Vivo Substances Profiling and Clinical Symptom-Guided Network Pharmacology

    by Guangyang Jiao, Xiangcheng Fan, Yejian Wang, Nan Weng, Luolan Ouyang, Haoqian Wang, Sihan Pan, Doudou Huang, Jun Han, Feng Zhang, et al.

    This work was aimed to elucidate the mechanism of action of Han-Shi-Yu-Fei-decoction (HSYFD) for treating patients with mild coronavi-rus disease 2019 (COVID-19) based on clinical symptom-guided network pharmacology. Experimentally, an ultra-high performance liquid chromatog-raphy technique coupled with quadrupole time-of-flight mass spectrometry method was used to profile the chemical components and the absorbed prototype constituents in rat serum after its oral administration, and 11 out of 108 compounds were identified. Calculatingly, the disease targets of Han-Shi-Yu-Fei symptoms of COVID-19 were constructed through the TCMIP V2.0 database. The subsequent network pharmacology and molecular docking analysis explored the molecular mechanism of the absorbed prototype constituents in the treatment of COVID-19. A total of 42 HSYFD targets oriented by COVID-19 clinical symptom were obtained, with EGFR, TP53, TNF, JAK2, NR3C1, TH, COMT, and DRD2 as the core targets. Enriched pathway analysis yielded multiple COVID-19-related signaling pathways, such as the PI3K/AKT signaling pathway and JAK-STAT pathway. Molecular docking showed that the key compounds, such as 6-gingerol, 10-gingerol, and scopoletin, had high binding activity to the core targets like COMT, JAK2, and NR3C1. Our work also verified the feasibility of clinical symptom-guided network pharmacology analysis of chemical compounds, and provided a possible agreement between the points of views of traditional Chinese medicine and western medicine on the disease.